IndiumV2, Main, Exploration, bibRecord, 001A49

Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. Studies with cell lines and animal studies.

Identifieur interne : 001A49 ( Main/Exploration ); précédent : 001A48; suivant : 001A50

Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. Studies with cell lines and animal studies.

Auteurs : RBID : pubmed:20126826

English descriptors

KwdEn :
- Animals, Antibodies, Monoclonal (immunology), Antibodies, Monoclonal (therapeutic use), Antigens, CD30 (antagonists & inhibitors), Antigens, CD30 (immunology), Cell Division, Cell Line, Tumor, Hodgkin Disease (pathology), Hodgkin Disease (radiotherapy), Humans, Indium Radioisotopes (pharmacokinetics), Indium Radioisotopes (therapeutic use), Iodine Radioisotopes (pharmacokinetics), Iodine Radioisotopes (therapeutic use), Mice, Radiotherapy (adverse effects), Radiotherapy Dosage, Tissue Distribution.
MESH :
- chemical , antagonists & inhibitors : Antigens, CD30.
- chemical , immunology : Antibodies, Monoclonal, Antigens, CD30.
- chemical , pharmacokinetics : Indium Radioisotopes, Iodine Radioisotopes.
- chemical , therapeutic use : Antibodies, Monoclonal, Indium Radioisotopes, Iodine Radioisotopes.
- adverse effects : Radiotherapy.
- pathology : Hodgkin Disease.
- radiotherapy : Hodgkin Disease.
- Animals, Cell Division, Cell Line, Tumor, Humans, Mice, Radiotherapy Dosage, Tissue Distribution.

Abstract

Comparison of the binding affinity to a CD30-positive Hodgkin lymphoma (HL) cell line and biodistribution in HL bearing mice of new anti-CD30 radioimmunoconjugates (RICs) of varying structure and labelling nuclides.

DOI: 10.3413/nukmed-0258
PubMed: 20126826

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001B06
to stream Main, to step Curation: 001B06

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. Studies with cell lines and animal studies.</title>
<author><name sortKey="Dietlein, Markus" uniqKey="Dietlein M">Markus Dietlein</name>
<affiliation wicri:level="3"><nlm:affiliation>Department for Nuclear Medicine, University of Cologne, 50937 Cologne, Germany. markus.dietlein@uni-koeln.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department for Nuclear Medicine, University of Cologne, 50937 Cologne</wicri:regionArea>
<placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region>
<region type="district" nuts="2">District de Cologne</region>
<settlement type="city">Cologne</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="B Rner, S M" uniqKey="B Rner S">S M Börner</name>
</author>
<author><name sortKey="Fischer, T" uniqKey="Fischer T">T Fischer</name>
</author>
<author><name sortKey="Hansen, H" uniqKey="Hansen H">H Hansen</name>
</author>
<author><name sortKey="Schnell, R" uniqKey="Schnell R">R Schnell</name>
</author>
<author><name sortKey="Zimmermanns, B" uniqKey="Zimmermanns B">B Zimmermanns</name>
</author>
<author><name sortKey="Tawadros, S" uniqKey="Tawadros S">S Tawadros</name>
</author>
<author><name sortKey="Engert, A" uniqKey="Engert A">A Engert</name>
</author>
<author><name sortKey="Staak, O" uniqKey="Staak O">O Staak</name>
</author>
<author><name sortKey="Pogge Von Strandmann, E" uniqKey="Pogge Von Strandmann E">E Pogge von Strandmann</name>
</author>
<author><name sortKey="Kobe, C" uniqKey="Kobe C">C Kobe</name>
</author>
<author><name sortKey="Schicha, H" uniqKey="Schicha H">H Schicha</name>
</author>
<author><name sortKey="Schom Cker, K" uniqKey="Schom Cker K">K Schomäcker</name>
</author>
</titleStmt>
<publicationStmt><date when="2010">2010</date>
<idno type="doi">10.3413/nukmed-0258</idno>
<idno type="RBID">pubmed:20126826</idno>
<idno type="pmid">20126826</idno>
<idno type="wicri:Area/Main/Corpus">001B06</idno>
<idno type="wicri:Area/Main/Curation">001B06</idno>
<idno type="wicri:Area/Main/Exploration">001A49</idno>
</publicationStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Monoclonal (immunology)</term>
<term>Antibodies, Monoclonal (therapeutic use)</term>
<term>Antigens, CD30 (antagonists & inhibitors)</term>
<term>Antigens, CD30 (immunology)</term>
<term>Cell Division</term>
<term>Cell Line, Tumor</term>
<term>Hodgkin Disease (pathology)</term>
<term>Hodgkin Disease (radiotherapy)</term>
<term>Humans</term>
<term>Indium Radioisotopes (pharmacokinetics)</term>
<term>Indium Radioisotopes (therapeutic use)</term>
<term>Iodine Radioisotopes (pharmacokinetics)</term>
<term>Iodine Radioisotopes (therapeutic use)</term>
<term>Mice</term>
<term>Radiotherapy (adverse effects)</term>
<term>Radiotherapy Dosage</term>
<term>Tissue Distribution</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Antigens, CD30</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Antigens, CD30</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Indium Radioisotopes</term>
<term>Iodine Radioisotopes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Indium Radioisotopes</term>
<term>Iodine Radioisotopes</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Radiotherapy</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Hodgkin Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Hodgkin Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Division</term>
<term>Cell Line, Tumor</term>
<term>Humans</term>
<term>Mice</term>
<term>Radiotherapy Dosage</term>
<term>Tissue Distribution</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Comparison of the binding affinity to a CD30-positive Hodgkin lymphoma (HL) cell line and biodistribution in HL bearing mice of new anti-CD30 radioimmunoconjugates (RICs) of varying structure and labelling nuclides.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20126826</PMID>
<DateCreated><Year>2010</Year>
<Month>05</Month>
<Day>27</Day>
</DateCreated>
<DateCompleted><Year>2010</Year>
<Month>08</Month>
<Day>16</Day>
</DateCompleted>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0029-5566</ISSN>
<JournalIssue CitedMedium="Print"><Volume>49</Volume>
<Issue>3</Issue>
<PubDate><Year>2010</Year>
</PubDate>
</JournalIssue>
<Title>Nuklearmedizin. Nuclear medicine</Title>
<ISOAbbreviation>Nuklearmedizin</ISOAbbreviation>
</Journal>
<ArticleTitle>Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. Studies with cell lines and animal studies.</ArticleTitle>
<Pagination><MedlinePgn>97-105</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3413/nukmed-0258</ELocationID>
<Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Comparison of the binding affinity to a CD30-positive Hodgkin lymphoma (HL) cell line and biodistribution in HL bearing mice of new anti-CD30 radioimmunoconjugates (RICs) of varying structure and labelling nuclides.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">The antibodies Ki-4 and 5F11 were radioiodinated by the chloramine T method or labelled with (111)In via p-NCS-Benzyl-DOTA. In addition, the Ki-4-dimer was investigated in the iodinated form. The RICs were analyzed for retained immunoreactivity by immunochromatography. In-vitro binding studies were performed on CD30-positive L540 cell lines. For in-vivo biodistribution studies, SCID mice bearing human HL xenografts were injected with the various radioimmunoconjugates. After 24 h, activities in the organs and tumour were measured for all 5 RICs. Tumour-free animals were studied in the same way with (131)I- Ki-4 24 h p. i. The three RICs with the highest tumour/background ratios 24 h p.i. ((131)I-Ki-4, (131)I-5F11, (111)In-bz-DOTA-Ki-4) were analysed further at 48 h and 72 h.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">All the RICs were successfully labelled with high specific activities (28-47 TBq/mmol) and sufficient radiochemical yields (>80%). Scatchard plot analysis proved high tumour affinity (KD = 20-220 nmol/l). In-vivo tumour accumulation in % of injected dose per g tissue (%ID/g) lay between 2.6 ((131)I-5F11) and 12.3 % ID/g ((131)I-Ki-4) with permanently high background in blood. Tumour/blood-ratios of all RICs were below one at all time points.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In-vitro tumour cell affinities of all RICs were promising. However, in-vivo biokinetics tested in the mouse model did not meet expectations. This highlights the importance of developing and testing further new anti-CD30 conjugates.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dietlein</LastName>
<ForeName>Markus</ForeName>
<Initials>M</Initials>
<Affiliation>Department for Nuclear Medicine, University of Cologne, 50937 Cologne, Germany. markus.dietlein@uni-koeln.de</Affiliation>
</Author>
<Author ValidYN="Y"><LastName>Börner</LastName>
<ForeName>S M</ForeName>
<Initials>SM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Fischer</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hansen</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Schnell</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zimmermanns</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tawadros</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Engert</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Staak</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
</Author>
<Author ValidYN="Y"><LastName>Pogge von Strandmann</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kobe</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Schicha</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Schomäcker</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2010</Year>
<Month>02</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>Nuklearmedizin</MedlineTA>
<NlmUniqueID>7609387</NlmUniqueID>
<ISSNLinking>0029-5566</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Antigens, CD30</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Indium Radioisotopes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Iodine Radioisotopes</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName MajorTopicYN="N">immunology</QualifierName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Antigens, CD30</DescriptorName>
<QualifierName MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Cell Division</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Hodgkin Disease</DescriptorName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="Y">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName>
<QualifierName MajorTopicYN="Y">pharmacokinetics</QualifierName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Iodine Radioisotopes</DescriptorName>
<QualifierName MajorTopicYN="Y">pharmacokinetics</QualifierName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Radiotherapy</DescriptorName>
<QualifierName MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Radiotherapy Dosage</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Tissue Distribution</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year>
<Month>6</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2010</Year>
<Month>1</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="aheadofprint"><Year>2010</Year>
<Month>2</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2010</Year>
<Month>2</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2010</Year>
<Month>2</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2010</Year>
<Month>8</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pii">0258</ArticleId>
<ArticleId IdType="doi">10.3413/nukmed-0258</ArticleId>
<ArticleId IdType="pubmed">20126826</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=IndiumV2/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A49 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A49 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=   *** parameter Area/wikiCode missing *** 
   |area=    IndiumV2
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:20126826
   |texte=   Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. Studies with cell lines and animal studies.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:20126826" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a IndiumV2

This area was generated with Dilib version V0.5.76.
Data generation: Tue May 20 07:24:43 2014. Site generation: Thu Mar 7 11:12:53 2024

	Serveur d'exploration sur l'Indium
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur l'Indium

Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. Studies with cell lines and animal studies.

Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. Studies with cell lines and animal studies.

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki